In Proof-of-Concept NSCLC Trial, Mythic Hoping to Show Broad Utility of Antibody-Drug Conjugate

The firm has designed its lead candidate, MYTX-011, to treat NSCLC patients with high to low cMET-expressing tumor cells.

Related Keywords

United States ,Waltham ,Massachusetts ,American ,Merck Kgaa Tepmetko ,Brian Fiske ,Genentech Kadcyla ,Novarti Tabrecta ,Immunogen Elahere ,Astrazeneca Enhertu ,Seagen Tivdak ,Daiichi Sankyo ,American Association For Cancer Research ,Mythic Therapeutics ,American Association ,Cancer Research ,Gilles Gallant ,